Elodie Amour
Paris, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Circulating epigenetic and epitranscriptomic biomarkers identify EGFR status, predict TKI response and reveal therapeutic vulnerabilities in NSCLC.
Journal: Scientific reports
Published: March 09, 2026
Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: October 15, 2025
Prognostic Value of FDG PET Metabolic Parameters Before and After 42 Gy of Radiochemotherapy in Patients with Inoperable Stage III Nonsmall Cell Lung Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: August 29, 2024
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial.
Journal: The Lancet. Oncology
Published: March 14, 2024
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 18, 2023
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 15, 2021
First-Line Afatinib plus Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 26, 2020
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 21, 2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Journal: The Lancet. Oncology
Published: August 02, 2018
IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer
Journal: Revue des maladies respiratoires
Published: December 19, 2017
Showing 1-10 of 10
Last Updated: 09/26/2026